Navigation Links
Monsanto Company Signs Share Subscription Agreement With Devgen
Date:9/14/2007

GHENT, Belgium and ST. LOUIS, Sept. 14 /PRNewswire-FirstCall/ -- Devgen (Eurolist: DEVG) and Monsanto Company (NYSE: MON) today announced that they have signed an agreement in which Monsanto has agreed, subject to certain customary conditions, to subscribe to 1,045,400 Devgen shares at 17.22 euro/share, totaling euro 18 million (25 million $) and representing 5.9% of the outstanding capital of Devgen NV. Closing is expected to take place no later than November 2007.

It is anticipated that Monsanto's becoming a shareholder of Devgen will complement the ongoing collaboration and technology exchange agreements of the companies.

"Devgen has served as a key collaborator with our technology organization for several years," said Robb Fraley, Ph.D., Chief Technology Officer at Monsanto. "We're excited to build upon our strong working relationship with Devgen. We believe this is an important part of supporting our collective mission of discovering and delivering new agricultural technologies to the farm."

"We welcome Monsanto as a shareholder," said Thierry Bogaert, Chief Executive Officer of Devgen. "This strengthens Devgen's ability to develop and commercialize innovative biotech traits and seeds that meet farmers' needs."

Pol Bamelis, Chairman of Devgen, added: "We are pleased to strengthen our relationship with Monsanto. I would like to take the opportunity to acknowledge the merits of my predecessor, Mr Pierre Hochuli, in forging this relationship and to thank him sincerely for his significant contribution to Devgen's progress during his 5-year tenure as chairman of Devgen."

About Devgen

Devgen is a top 10 public agro biotech company with agricultural business units focused on developing and commercializing:

-- a novel generation of biotech products to protect a wide spectrum of

crops from damage incurred from pests;

-- biotech traits and germplasm to meet the growing needs for high

yielding, high quality hybrid rice and selected small grains in India

and S.E. Asia;

-- safer and more environmentally friendly agro-chemical products to

protect crops from damage inflicted by plant parasitic nematodes.

Devgen's biopharmaceutical division develops a new class of preclinical drug candidates, based on novel therapeutic concepts, for treatment of a range of inflammatory metabolic diseases (diabetes, obesity) and arrhythmia.

Devgen has entered in partnerships with industry leaders in biotechnology and agro chemistry. Incorporated in 1997, Devgen has offices in Ghent (Belgium), Singapore and Hyderabad (India), with a total work force of about 100 people. Devgen is listed on Eurolist by Euronext Brussels (ticker: DEVG) since June 2005. For more information on Devgen, please visit the company's web site: http://www.devgen.com.

About Monsanto

Monsanto Company is a leading global provider of technology-based solutions and agricultural products that improve farm productivity and food quality. For more information on Monsanto, see: http://www.monsanto.com.

This press release may contain forward-looking statements containing the words "anticipates," "expects," "intends," "plans," "estimates," "may" and "continues" as well as similar expressions. Such forward looking statements may involve known and unknown risks, uncertainties and other factors which might cause the actual results, performance or achievements of Devgen to be materially different from any future results or achievements expressed or implied by such forward-looking statements. These forward looking statements speak only as of the date of publication of this document. Devgen disclaims any obligation to update such forward looking statements in this document to reflect any change in its expectations, conditions or circumstances on which such statement is based, unless required by law or regulation.


'/>"/>
SOURCE Monsanto Company
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. Germantown drug company hires pharma veteran James Davidson as COO
2. Georgia stem cell company likely to stay put
3. Surgical products company wins Governors Business Plan Contest
4. Madison stem cell company gets $1M from state
5. Company still behind schedule on Milwaukee wireless project
6. Software company enters health space with RFID solutions on hold
7. Delaware company will keep NameProtect here
8. IPO-bound NimbleGen traveling in fast company
9. Wisconsin tries to woo another stem cell company
10. Company to operate in wireless Internet space
11. RedPrairie acquires Denver software company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... DIEGO , Feb. 5, 2016 On ... region,s trusted information source for community, health and disaster ... Diego) will integrate to enhance care coordination and ... to the services they need and to better connect ... improve care.   San Diego ...
(Date:2/4/2016)... - New FDA action date of July ... action date of July 22, 2016   --> ... 22, 2016   - Lifitegrast has the ... for the treatment of signs and symptoms of dry eye disease ... to be the only product approved in the U.S. in the past decade indicated for ...
(Date:2/4/2016)... SHENZHEN, China , Feb. 4, 2016 ... government, and various medical institutions attended a ceremony in ... provide integrative, personalized cell therapy in 2016. ... the "Shenzhen Clinical Translation Platform for Personalized Cell Therapy" ... Shenzhen Regional Cell Production Center, both subsidiaries of Beike ...
(Date:2/4/2016)... Feb. 4, 2016 ContraVir Pharmaceuticals, Inc. (NASDAQ: ... development and commercialization of targeted antiviral therapies, announced today ... Conference 2016, to be held February 8-9, 2016, at ... 2016 Disruptive Growth & Healthcare Conference, taking place in ... 2016. James Sapirstein , Chief Executive Officer ...
Breaking Biology Technology:
(Date:2/3/2016)... , February 4, 2016 --> ... to SEK 1,351.5 M (105.0), up 1,187% compared with fourth quarter of ... amounted to SEK 517.6 M (loss: 30.0). Earnings per share ... activities was SEK 537.4 M (neg: 74.7). , ... , Revenues amounted to SEK 2,900.5 M (233.6), up 1,142% compared with ...
(Date:2/2/2016)... NEW YORK , Feb. 2, 2016 /PRNewswire/ ... analysis of the bioinformatic market by reviewing the ... computer enabled tools that drive the field forward. ... report to: Identify the challenges and opportunities ... service providers and software solution developers, as well ...
(Date:2/1/2016)... BURNABY, Canada , February 1, 2016 ... new technological advancements to drive global touchfree intuitive gesture ...   --> Rising sales of consumer electronics ... intuitive gesture control market size ... of consumer electronics coupled with new technological advancements to ...
Breaking Biology News(10 mins):